Skip to content

Protected: Studies

A Randomized, Double-Blind, Placebo-Controlled, Two Dose-Arm, Parallel Study of the Safety and Effectiveness of Immune Globulin Intravenousfor the Treatement of Mild-to-Moderate Alzheimer's Disease

Calendar Name IGIV
Description This study is to evaluate whether the use of intravenous immune globulin (also called “IGIV”) is able to change the rate of memory decline and daily functioning in subjects with mild to moderate Alzheimer’s disease (AD). IGIV is obtained from plasma of healthy blood donors and contains special proteins called “antibodies” that help protect the body against infection and other illnesses. Subjects who are qualified for participation in this study are currently taking medication approved for the treatment of AD. IGIV has been approved to treat several disorders; but we do not know yet whether the use of IGIV can help AD. In this trial, subjects will be randomized into three groups: placebo, low-dose and high-dose groups.
PI Chuang-Kuo Wu
Business Administrator -
Resources 1.5T Aera
IRB STU00009289
Start Date
End Date
Chart String 640-5404000-60024326-01
Affiliates No